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Predicting response to treatment and disease-specific deaths
are key tasks in cancer research yet there is a lack of
methodologies to achieve these. Large-scale ’omics and digital
pathology technologies have led to the need for effective
statistical methods for data fusion to extract the most useful
patterns from these diverse data types. We present FusionGP,
a method for combining heterogeneous data types designed
specifically for predicting outcome of treatment and disease.
FusionGP is a Gaussian process model that includes a
generalization of feature selection for biomarker discovery,
allowing for simultaneous, sparse feature selection across
multiple data types. Importantly, it can accommodate highly
nonlinear structure in the data, and automatically infers the
optimal contribution from each input data type. FusionGP
compares favourably to several popular classification methods,
including the Random Forest classifier, a stepwise logistic
regression model and the Support Vector Machine on single
data types. By combining gene expression, copy number
alteration and digital pathology image data in 119 estrogen
receptor (ER)-negative and 345 ER-positive breast tumours,
we aim to predict two important clinical outcomes: death and
chemoinsensitivity. While gene expression data give the best
predictive performance in the majority of cases, the digital
pathology data are much better for predicting death in ER cases.
Thus, FusionGP is a new tool for selecting informative features
from heterogeneous data types and predicting treatment
response and prognosis.
1. Introduction
Post-genomic molecular biology is revolutionizing the study of
cancer [1,2]. New measurement technologies are giving us fresh
insights into the molecular and genetic mechanisms underlying
the disease, and modelling these data gives us ways to predict
2016 The Authors. Published by the Royal Society under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted
use, provided the original author and source are credited.




the likely progression and outcome of disease in a given patient [3,4]. By identifying informative
markers related to critical events, there is unprecedented potential for both the development of new
prognostic/diagnostic tests, and also for furthering our understanding of cancer’s key driving molecular
and genetic mechanisms.
The digitisation of high-quality tumour pathology images now gives us a complementary perspective
at the point of diagnosis [5]. Tumour cells can be identified in these images computationally and the
resulting data on cell morphology and spatial distribution used as an additional source of information in
analysing a given cancer case. We therefore have access to multiple data types for a given cancer patient.
The most effective prediction of clinical outcomes then requires that we develop statistical algorithms
that are able to effectively combine these diverse data types. This presents several challenges which we
aim to address in this paper.
(i) Challenge 1: outcome prediction. Given a training set of measurements, we wish to predict the
likely outcomes of treatment or prognosis for a new patient for whom we have analogous
measurements. This can inform clinicians of the likely disease course and hence help design
efficient treatment strategy.
(ii) Challenge 2: biomarker discovery. The available data are often high-dimensional. By identifying in a
principled way which features are informative by allowing for the possibility of sparse solutions,
we identify a small subset of the features are informative about clinical outcome.
(iii) Challenge 3: effective integration of multiple data types. To get the best possible results, we should
include all relevant information and do so in a principled way. In particular, different types of
data offer complementary perspectives on a given disease. We, therefore, wish to generalize the
notion of feature selection to include multiple, possibly heterogeneous data types.
There have been a number of previous attempts to address various of these challenges, for example,
Futschik et al. [6], Nevins et al. [7], Pittman et al. [8], Stephenson et al. [9], Gevaert et al. [10], Boulesteix et al.
[11], Daemen et al. [12], Obulkasim et al. [13]. However, the field as yet lacks a comprehensive framework
that is suitable for combining data from the types of highly heterogeneous biomedical data that are being
generated in increasingly large volumes. To address this, we adopt a statistical modelling approach. Such
a model must be able to handle high-dimensional, noisy data in a principled way and must be capable
of learning a wide range of possible structure. Non-parametric Bayesian models provide just such a
framework. By learning a level of structure appropriate to the data, they naturally encode a kind of
Occam’s razor, and their Bayesian nature lends itself naturally to the inclusion of multiple sources of
data and/or prior knowledge. We have previously developed Bayesian non-parametric models for data
integration in an unsupervised setting, e.g. Savage et al. [14], Yuan et al. [15], Kirk et al. [16], but there is
much work still to be done in the supervised setting.
2. Material and methods
We present FusionGP, a Bayesian non-parametric method for integrating multiple data types, to perform
classification and sparse biomarker discovery. The relationship between input features and outcome is
modelled via a set of unknown latent functions (one per data type) that are constrained via a set of
Gaussian process (GP) priors. The input features for each data type are selected via a slab-and-spike
prior, where the probability of a feature being switched on is inferred as part of the inference process,
allowing for sparse feature selection in a given data type, where the data support it.
2.1. Gaussian processes
We model the relationship between each data type and the target values via (unknown) latent functions.
We assume the latent functions to be realizations of a zero-mean GP [17], noting that this approach has a
successful track record in modelling molecular data [18–20].
For convenience, we adopt a compact notation for the latent function for the dth data type, fd.
Given this, we define the following GP prior over the space of unknown functions for the dth data
type:
P( f d) = (2π )−n/2|K|−1/2exp
(
− 12 f dT(K)−1f d
)
. (2.1)
For n data points, and where K is the N × N covariance matrix that defines the GP.





For GP models, the features contribute via the covariance function. To allow feature selection, we define
additional indicator parameters, Ijd for the jth feature in the dth data type . When Ijd = 1, the jth feature
is switched on and behaves as usual. When Ijd = 0, the feature is excluded from the analysis. In molecular
data, we expect that in general the number of features that are informative may be relatively small. We,
therefore, apply a sparsity prior to the Ijd, to encode this knowledge:
P(Ijd) ∝ 2−adwadd (1 − wd)Jd−ad , (2.2)
where ad = ΣjIjd, the number of features switched on in data type d and Jd is the total number of features
in data type d.
This is, therefore, a product of Bernoulli distributions (one per indicator parameter), with an
additional factor of 2−ad which penalizes individual features being switched on. This equation is,
therefore, the joint distribution for all Ijd for a given data type.
The hyperparameters wd are inferred and allow the model to determine the appropriate level of
sparsity, given the data. We apply a binomial prior on wd, using this to encode our prior belief that at
least a small number of the features will be informative. We also enforce a hard prior of wd ≤ 0.5, because
we do not wish the prior itself to favour switching features on:
w∼ β(10, 10). (2.3)
2.3. Covariance function
One of the great advantages of GP models is that we have access to a wide range of covariance functions,
all using the same overall model framework. For the synthetic data analyses in this paper, we use four
different covariance functions:
Klinear(xi, xj) =A0 + xi.xj, (2.4)






















and Ksum(xi, xj) =Klinear(xi, xj) + KSE(xi, xj), (2.7)
where ‘SE’ stands for ‘square exponential’ and r= |xi − xj|.
For simplicity, all analyses presented in this paper use the same covariance function for data types in
said analysis. This is chosen for convenience—FusionGP does not require this. FusionGP uses the GPML
MATLAB library [21], which means that it can be run with a wide range of different covariance functions.
We are grateful to the GPML authors for their provision of this library and would recommend it highly
to anyone working with GPs in MATLAB.
2.4. Model specification
To model binary outcomes, we choose the probit function [22]:
P(D|fd) ∼ probit. (2.8)
We model each data type using an (unknown) latent function, that relates the input features x to the
outcome of interest, y, via the probit likelihood. We wish these latent functions to be highly flexible so
that they can capture the complex biological structure underlying the data. We therefore choose to draw
the latent functions from zero-mean GPs:
f d ∼ GP(0,Kd). (2.9)
To include information from multiple data sources, we use the approach of Girolami & Zhong [23].
In this approach, we assume that the datasets are conditionally independent of one another given the
target values. This results in a model that is easy to work with and is nevertheless extremely powerful.
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Figure 1. (a) The aim of FusionGP is to predict clinical outcome such as chemoinsensitivity by integrative analysis of multiple data types.
(b) Graphical model for FusionGP. yi are the target labels. fdi is the latent function value for the ith data item in the dth data type. θd are
the hyperparameters that define the covariance function for the dth data type. Xdi is the data value for the ith data item in the dth data
type. Ijdd is the feature selection indicator parameter for the jdth feature in the dth data type. wd are the hyperparameters that encode
sparsity in the feature selection.





where Ad is the scaling parameter for the dth latent function. We note that this model has the great
merit of scaling well with the number of datasets. For example, the number of covariance parameters is
proportional to the number of datasets.
The features in each data type are assigned indicator parameters, Ijd, subject to the sparsity priors
discussed in the above section on feature selection. The covariance matrix for a given data type is
computed using only the features for which Ijd = 1. This, therefore, encodes sparse feature selection into
the FusionGP model. A graphical model representation of the FusionGP model is shown in figure 1.





Owing to the form of the likelihood, this model does not have a closed form. We, therefore, use Markov
chain Monte Carlo (MCMC) to perform inference. The challenge in doing this is one of computation time.
MCMC analysis typically requires at least O(104 − 105) evaluations of the likelihood, and inference with
GPs requires Cholesky decompositions of the covariance matrix for each evaluation, which scale as the
cube of the number of data items. For types of data considered in this paper, the number of data items
will be tractable.
In the context of GPs, Cholesky decompositions tend to become challenging to use for more than
O(104) data items. Given that this method uses MCMC (rather than parameter optimization), we suspect
that for more than a few thousand data items, the proposal model will be sufficiently slow as to be
intractable. However, there are now many effective ways to scale GPs to larger numbers of data items,
so this would probably provide a plausible way forward in such cases.
We note that the Cholesky decomposition has no dependence on the number of features. For the
covariance functions considered in this paper, computing the covariance matrix is linear in the number
of features, and will typically not be the dominant step in the algorithm. FusionGP, therefore, scales
extremely well with the both the number of features in each data type, and also the total number of
features across all data types.
We sample the logarithm of the covariance hyperparameters (wd and Ad) using a Metropolis–Hastings
algorithm with Gaussian proposal distribution, the variance of which we tune using samples from an
initial burn-in period of the MCMC chain. We choose to work with the log-parameters for convenience
as the parameters cannot take negative values.
When using GPs, we marginalize over the (unknown) latent function. Because in FusionGP the
likelihood is not closed form, we do this as part of the MCMC algorithm. Specifically, we define a set of
parameters that are the latent function values at the training points. We sample these using a Metropolis–
Hastings algorithm with Gaussian proposal distribution, with variance again tuned using samples from
an initial burn-in period of the MCMC chain. The latent function values are then effectively marginalized
as part of the MCMC sampling process. We note that there are more sophisticated sampling schemes that
one could use here, such as elliptical slice sampling [24]. We found a simpler scheme adequate for the
results presented in this paper, but future improvements can certainly be made to the sampling scheme.
2.6. Markov chain Monte Carlo performance
For each analysis in this paper, we run five MCMC chains and combine the results, after removing the
first 50% as burn-in and sparse-sampling the chains by a factor of 10. Each chain is run for 48 h in the
University of Warwick’s High Performance Computing cluster. The results presented in this paper are,
therefore, produced using a fixed total run-time.
We note that MCMC convergence can be challenging for models dealign with high-dimensional
feature selection, and FusionGP is no exception. We assess the convergence of our analyses by looking by
eye at a range of one-dimensional marginal posteriors (histograms), comparing the equivalent plot for
each of the chains (which should give the same distribution if the chains are converged). This could be
further improved in future by taking a more in-depth statistical approach, but our practical experience
is that this approach works well in practice.
3. Examples
We validate FusionGP on both synthetic and real breast cancer data. The synthetic data are generated to
provide a rigorous test of FusionGP’s performance where the ground truth is known, and to facilitate
comparisons with existing methods. The breast cancer dataset is taken from the recently published
METABRIC study of over 2000 patients [25].
3.1. Synthetic data
We generate two synthetic data types, each with the same underlying signal, and different noise
realizations drawn from the same Gaussian distribution. These data are designed to represent the case
where we have a significant number of features, of which a relatively small proportion are informative.
Each data type contains 500 items (250 outcome = true and 250 outcome = false cases). There are 600
features, 100 of which contain signal and the remaining 500 of which contain only noise. Each signal




feature is generated by taking the known target values and adding Gaussian noise, whose variance is
fixed for a given data type. The noise features are generated solely by drawing from the same Gaussian
noise distribution, i.e. without any signal.
3.2. METABRIC breast cancer data
METABRIC is a large-scale study of the genomic and transcriptomic landscape of breast cancer [25].
The METABRIC data contains copy number, gene expression, histopathological haematoxylin and eosin
(H&E) images, and clinical information for over 2000 patients. H&E stained images of tumour slides
are potentially highly complementary to the molecular data types. The METABRIC images have been
quantitatively analysed by Yuan et al. [5]. Nuclear morphological features of different types of cells
including cancer, lymphocytes and stromal cells which include fibroblasts and endothelial cells were
quantitatively measured. These features include topological and image moment features to measure
elongation, size, texture, etc., yielding 100 features in total. Median, variance and skewness were used to
characterize the distribution of nuclear features in each tumour. As a result, we obtained imaging data
for each patient tumour where each of the morphological features was summarized by median, variance
or skewness, totalling 900 features.
We considered two clinical outcomes: death and chemoinsensitivity. All are defined as binary
outcomes for simplicity of modelling. This will result in some information loss on the case of death,
which would be more properly modelled as a (censored) survival time. However, this choice allows us to
focus in paper more on other aspects of the model. We, therefore, considered only samples from patients
who have either survived for 10 years, or who are confirmed to have died prior to that point. This leaves
us with 464 samples for which we have copy number, gene expression and image feature data. Of these
464 samples, 119 were estrogen receptor (ER) negative (ER−) and 345 were ER positive (ER+). In addition
to analysing the whole set of samples, we also considered the ER− and ER+ subsets, as these subsets are
biologically distinct disease from one another. We, therefore, define the clinical outcomes as follows.
— Death. The patient died of breast cancer within 10 years of diagnosis with breast cancer.
— Chemoinsensitivity. The patient died (as above) and had been treated with chemotherapy.
4. Results
4.1. Results on synthetic data
Tables 1 and 2 show the results of FusionGP analyses of the synthetic data. Table 2 gives ‘oracle’ results,
where only ‘signal’ features are used in the analysis. Table 1 gives the results for the case where the correct
features are not known, so the algorithm must use feature selection. Comparing the two sets of results,
we can see that while the presence of noise features has an adverse impact on the outcome prediction area
under curve (AUC), we are still able to make useful predictions even when there are five times as much
noise as informative features. The biomarker AUC values show that correctly identifying the informative
‘biomarker’ features is more challenging than simply making predictions. This may be an indication as
to one reason why biomarker discovery in genomic cancer data has proven such a challenge to date.
Table 3 shows comparison analyses using the Random Forest (RF) model [26], a stepwise logistic
regression generalized linear model (GLM) method and a simple Support Vector Machine (SVM) with
no feature selection. These represent well-known classification algorithms that would be sensible default
choices for analysis of single data types such as those considered in this paper. The results show that all
three comparison methods are significantly impacted by the presence of large numbers of noise features,
under-performing in comparison to FusionGP. We also note that even in the oracle case, FusionGP shows
somewhat superior performance.
4.2. Results on METABRIC data
We ran twofold cross-validation analyses to assess the performance of FusionGP on the METABRIC
breast cancer data. For these analyses, we chose the SE covariance function, as it was best-performing on
the synthetic data runs. Tables 4–6 show the prediction AUC from the cross-validation. We compared the
AUC scores of FusionGP and each of the three comparison methods. The differences are computed for
each single data type comparison in tables 4–6. Figure 2 shows scatter plots of the single data type results
for FusionGP. Comparing the distributions of AUC scores for each method using the Wilcoxon rank sum




Table 1. Synthetic data results. (Shown are area-under-curve (AUC) values from receiver operating characteristic (ROC) curves for both
outcome and biomarker predictions.)
run covar. outcome AUC biomarker AUC
synth. (2 types) SE 0.74± 0.04 0.59± 0.08
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (2 types) Matern 0.70± 0.02 0.59± 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (2 types) sum 0.70± 0.02 0.58± 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (2 types) linear 0.71± 0.01 0.59± 0.10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (1 type) SE 0.68± 0.04 0.68± 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (1 type) Matern 0.68± 0.04 0.62± 0.14
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (1 type) sum 0.69± 0.04 0.62± 0.11
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (1 type) linear 0.68± 0.04 0.66± 0.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Synthetic data ‘oracle’ results, where the correct features are known. (Shown are area-under-curve (AUC) values from ROC
curves.)
run covar. outcome AUC
oracle (2 types) linear 0.86± 0.02
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (2 types) SE 0.87± 0.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (2 types) Matern 0.86± 0.02
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (2 types) sum 0.86± 0.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) linear 0.78± 0.05
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) SE 0.79± 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) Matern 0.79± 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) sum 0.79± 0.05
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Synthetic data results for comparisonmethods. (For the ‘oracle’ runs, only the informative features are included in the analysis.)
data method prediction AUC biomarker AUC
synth. (1 type) RF 0.63± 0.03 0.57± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (1 type) stepwise GLM 0.61± 0.03 0.54± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
synth. (1 type) SVM (no selection) 0.66± 0.02 —
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) RF 0.74± 0.01 —
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) stepwise GLM 0.74± 0.01 —
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
oracle (1 type) SVM (no selection) 0.75± 0.03 —
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
test, we obtain p= 0.66 (RF), 8 × 10−4 (stepwise GLM) and 4 × 10−3 (SVM). We therefore conclude that
FusionGP significantly outperforms both stepwise GLM and SVM methods, and marginally outperforms
RF for the METABRIC data types.
For analysis using death as outcome, we found a striking difference between the ER− and ER+ item
subsets. For the ER+ items, the molecular data are highly informative. However, the combination of copy
number and gene expression data produce results consistent with those obtained for gene expression
alone. We suggest that this is due to a duplication of information in that the effect of the gene expression
accompany copy number alteration. In ER− tumours both molecular data types are poorly informative.
The image features, however, are highly informative, suggesting that cell morphology information are
important in predicting survival in breast cancer.




Table 4. ROC curve AUC results from analysing different combinations of METABRIC data types. (The best-performing method/s in each
row are highlighted in bold. CN, copy number; GE, gene expression.)
data FusionGP RF GLM SVM
chemoinsens. CN 0.72± 0.01 0.68± 0.01 0.63± 0.05 0.61± 0.06
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE 0.78± 0.02 0.74± 0.02 0.71± 0.01 0.70± 0.02
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
image 0.55± 0.04 0.58± 0.06 0.58± 0.01 0.57± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE/CN 0.78± 0.02 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all 0.78± 0.03 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
death CN 0.69± 0.01 0.68± 0.01 0.53± 0.02 0.62± 0.08
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE 0.75± 0.01 0.74± 0.01 0.64± 0.05 0.68± 0.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
image 0.60± 0.01 0.59± 0.01 0.49± 0.02 0.60± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE/CN 0.75± 0.01 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all 0.75± 0.01 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5. ROC curve AUC results, using only the 119 ER− patients. (The best-performing method/s in each row are highlighted in bold.)
data FusionGP RF GLM SVM
chemoinsens. CN 0.59± 0.10 0.60± 0.14 0.52± 0.07 0.54± 0.16
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE 0.59± 0.07 0.60± 0.02 0.51± 0.05 0.55± 0.02
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
image 0.61± 0.07 0.60± 0.03 0.55± 0.01 0.59± 0.10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE/CN 0.59± 0.11 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all 0.59± 0.08 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
death CN 0.56± 0.07 0.54± 0.06 0.51± 0.02 0.46± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE 0.55± 0.03 0.56± 0.06 0.51± 0.06 0.52± 0.04
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
image 0.72± 0.03 0.73± 0.04 0.69± 0.02 0.69± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE/CN 0.55± 0.02 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all 0.67± 0.01 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 6. ROC curve AUC results, using only the 345 ER+ patients. (The best-performing method/s in each row are highlighted in bold.)
data FusionGP RF GLM SVM
chemoinsens. CN 0.68± 0.01 0.62± 0.01 0.58± 0.03 0.62± 0.02
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE 0.70± 0.02 0.66± 0.03 0.64± 0.11 0.60± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
image 0.52± 0.04 0.58± 0.08 0.46± 0.08 0.50± 0.09
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE/CN 0.70± 0.02 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all 0.70± 0.03 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
death CN 0.71± 0.02 0.71± 0.03 0.58± 0.11 0.60± 0.03
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE 0.75± 0.01 0.74± 0.01 0.75± 0.01 0.68± 0.01
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
image 0.62± 0.04 0.64± 0.04 0.52± 0.04 0.60± 0.05
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GE/CN 0.75± 0.01 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
all 0.75± 0.01 — — —
.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
For predicting chemoinsensitivity, we found that for the ER+ samples the molecular data are most
informative. For the ER− samples, our results suggest all three data types contain some relevant
information. Of note for chemoinsensitivity is the performance of the all-samples case. The predictive
performance for this case is significantly better than that of either ER− or ER+ cases. There must,
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Figure 2. Scatter plots for outcome predictions of all patients, comparing results for single data types. Outcome, FALSE is shown in blue,
outcome, TRUE is shown in red. CN, copy number; GE, gene expression.
therefore, be significant information sharing between the ER− and ER+ cases, in contrast with the
analyses for death, where the two ER subsets are highly distinct.
We compared FusionGP for single data types to the RF, stepwise GLM (logistic regression) and
SVM with no feature selection. Of the outcome/single-data-type combinations considered in tables 4–6,
FusionGP is either the best performing method or within one standard deviation of the best result in
26 of the 27 cases. RF also performed well, with joint-best performance in 16 cases and overall best
performance in one case. Stepwise GLM and the SVM were generally outperformed by both FusionGP
and RF, with a few exceptions.
For the image features, we found that across all analyses about a third of them were selected. This
suggests that there is duplicate information, which is expected due to the nature of their construction.
For example, acircularity (median acirc) and HuÃT¸s first moment or I1 (median I1) both measure shape
irregularity. There is minimal downside here in terms of predictive performance, although it suggests
that it may be possible to construct a smaller set of equally informative image features, which would
have some benefit in terms of the run time of any analysis.
We analysed the most strongly selected features for each data type. For the molecular types, we
looked for enrichment in gene ontology (GO) ontologies and KEGG pathways. We focused on biological
process in GO to identify processes underlying features predicted to be informative for important
clinical phenomenon. Figure 3 shows specific biological processes enriched in copy number features
that were found to be predictive of chemoinsensitivity by our algorithm in ER− and ER+ tumours.
Multiple cell cycle processes forming large cell cycle modules are evident in both ER− and ER+ tumours,
signifying the role of cell-cycle pathways across ER status yet highlighting different cell-cycle phases
for different ER status, e.g. transition phases including G2/M and G1/S for ER− and G1 and G2 for
ER+. Notably, activation of innate immune response is significantly enriched in the selected features for
predicting chemoinsensitivity only in ER− tumours. This is consistent with recent evidences showing
the importance of immune response in achieving pathological complete response to chemotherapy in
ER− tumours [27,28]. Our result again confirmed their observations yet extended to the genomics level,
indicating specific genomic aberrations that could underly innate immune response and influence the
response of ER− patients to chemotherapy.
We examined copy number and gene expression features for predicting deaths in ER+ because of
their good performance as indicated in table 6. Compared with figure 3, large cell-cycle modules can also
be found in the biological processes enriched in both feature types (figure 4). Of particular note, however,
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Figure 3. Enrichment maps for chemoinsensitivity as outcome for (a) ER− and (b) ER+ tumours. Shown are biological process that are
statistically over-represented in the copy number features for the single data type FusionGP analysis, as determined by a hypergeometric
test (p< 1−4). The size of the red circles indicates the number of genes with a given pathway; the grey lines showwhere the same gene
is shared across a pair of pathways, with line thickness indicating the number of genes. Enrichment maps were generated using the R
package HTSanalyzeR. Singleton/unconnected nodes are not shown.
is the DNA repair processes enriched only in the copy number features. It is well known that BRCA1,
a key mediator of the DNA repair pathways, remain one of the most important genes for breast cancer.
Specifically for ER+ patients, loss of BRCA1-mediated transcriptional activation of ER expression can
lead to increased resistance to ER antagonists [29]. Thus, the presence of genomic features involved in
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Figure 4. Enrichment maps for deaths as outcome for (a) copy number and (b) expression features selected for ER+ tumours. Shown
are biological process that are statistically over-represented in the corresponding feature types for the single data type FusionGP analysis,
as determined by a hypergeometric test (p< 1−4).
DNA repair when predicting deaths in ER+ patients support the accuracy of our algorithm in searching
for biologically meaningful features.
Gene expression features useful for predicting ER+ deaths include those involved in angiogenesis
(figure 4b). This indicates that microenvironmental changes such as angiogenesis, which can be captured
by gene expression data generated from our whole-tumour material, can be found in patients with
poor prognosis. Angiogenesis is a known hallmark of poor prognosis in breast cancer as supported by
multiple lines of evidences [30]. Meanwhile, ER is known to be capable of mediating angiogenesis, but
its mechanism remains elusive Losordo & Isner [31], and our result here not only supports this but also
reveals specific genes from our unsupervised analysis that may help define the regulatory mechanism.
Taken together, results from our proposed model are supported by current knowledge of important
genomic aberrations and microenvironmental features implied in insensitivity to chemotherapy and
poor prognosis, in addition to identifying new features that can potentially help define mechanisms
of these critical events.






We have presented FusionGP, a non-parametric Bayesian method for combining multiple data types
to predict binary clinical outcomes. FusionGP generalizes the notion of feature selection for biomarker
discovery, allowing for simultaneous, sparse feature selection across multiple heterogeneous data types.
Results on synthetic data show that FusionGP is effective at making predictions using noisy, sparse
data and that it can identify the informative features. Combining two synthetic data types leads to
superior predictive results, and also that FusionGP outperforms the RFs classifier, stepwise logistic
regression and also a simple SVM. We suggest that this is because these standard methods do not
explicitly account for the sparse nature of the synthetic data.
We present a range of analyses of the METABRIC breast cancer dataset, including gene expression,
copy number alterations and H&E image-derived morphological feature data, and considering as
outcomes death and chemoinsensitivity. We note that because the results are for a single collection
of datasets, and using cross-validation rather than an independent test set, some caution in the
interpretation of these results is warranted. With this in mind, from these analyses we draw a number of
conclusions.
— FusionGP consistently outperforms both stepwise GLM and SVM methods, and marginally
outperforms RF for the METABRIC data types.
— For prediction of disease-specific death, the molecular data are highly informative for the
ER+ tumours, whereas for the ER− tumours the image features significantly outperform the
molecular data.
— The enriched biological processes for the ER+ cases highlight specific genomic alterations in the
DNA repair pathway, which is indicative of DNA repair-mediated ER expression activation and
imply an influence on response to ER treatment.
— For prediction of chemoinsensitivity, ER− and ER+ tumours share common cell-cycle-related
processes in the feature selected, yet differs in processes signifying the role of immune infiltration
in the microenvironment in response to chemotherapy in ER− tumours.
— We therefore conclude that it is important to account for both the ER subtypes and also common
underlying structure that is shared by all tumour samples.
We note that in practical terms, complex methods such as FusionGP have much longer run times than
many of the equivalent standard methods. For example, if one is interested mainly in making predictions
using the METABRIC data, one can achieve only marginally worse results using the much-quicker RF
algorithm. FusionGP does also give a useful ability to better explain the biology underlying the data, as
we have done in this paper. Nevertheless, we note that improvements to the run time of FusionGP would
greatly improve its utility.
Given these results, we believe a number of interesting future directions present themselves. The
image features, and to some extent the molecular features, contain significant redundancy. Developing
models that learn a new set of (uncorrelated) latent features, rather than simply selecting the existing
features, may allow us to refine our biological insights. It would also be interesting to encode
more complex structures between the different data types—for example, we know that copy number
alterations will effect gene expression patterns. Previous experience suggests that modelling such
structure can add significant complexity to the modelling process, but it is certainly worthy of further
investigation. Finally, fast approximations for the FusionGP algorithm will become increasingly valuable
as multi-type cancer datasets becoming increasingly large.
We live in an exciting time for cancer research, where a range of new measurement technologies are
giving us unprecedented access to the inner workings of tumours and cancer cells. Developing new
methods to better use this data is vital if we are to make the most of this wave of new data.
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